Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 235

1.

Leading edge or tumor core: Intratumor cancer stem cell niches in oral cavity squamous cell carcinoma and their association with stem cell function.

Chowdhury FN, Reisinger J, Gomez KE, Chimed TS, Thomas CM, Le PN, Miller B, Morton JJ, Nieto CM, Somerset HL, Wang XJ, Keysar SB, Jimeno A.

Oral Oncol. 2019 Oct 3;98:118-124. doi: 10.1016/j.oraloncology.2019.09.011. [Epub ahead of print]

PMID:
31586893
2.

MAPKAPK2 (MK2) inhibition mediates radiation-induced inflammatory cytokine production and tumor growth in head and neck squamous cell carcinoma.

Berggren KL, Restrepo Cruz S, Hixon MD, Cowan AT, Keysar SB, Craig S, James J, Barry M, Ozbun MA, Jimeno A, McCance DJ, Beswick EJ, Gan GN.

Oncogene. 2019 Aug 15. doi: 10.1038/s41388-019-0945-9. [Epub ahead of print]

PMID:
31417185
3.

Phase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205).

Gibson MK, Catalano P, Kleinberg LR, Staley CA 3rd, Montgomery EA, Jimeno A, Song WF, Mulcahy MF, Leichman LP, Benson AB 3rd.

Oncologist. 2019 Jun 21. pii: theoncologist.2018-0750. doi: 10.1634/theoncologist.2018-0750. [Epub ahead of print]

PMID:
31227647
4.

Macrophages Promote Growth of Squamous Cancer Independent of T cells.

Wu FL, Nolan K, Strait AA, Bian L, Nguyen KA, Wang JH, Jimeno A, Zhou HM, Young CD, Wang XJ.

J Dent Res. 2019 Jul;98(8):896-903. doi: 10.1177/0022034519854734. Epub 2019 Jun 12.

PMID:
31189369
5.

Inhibition of EphB4-Ephrin-B2 Signaling Reprograms the Tumor Immune Microenvironment in Head and Neck Cancers.

Bhatia S, Oweida A, Lennon S, Darragh LB, Milner D, Phan AV, Mueller AC, Van Court B, Raben D, Serkova NJ, Wang XJ, Jimeno A, Clambey ET, Pasquale EB, Karam SD.

Cancer Res. 2019 May 15;79(10):2722-2735. doi: 10.1158/0008-5472.CAN-18-3257. Epub 2019 Mar 20.

PMID:
30894369
6.

Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.

Duarte C, Jimeno A, Kessler ER.

Drugs Today (Barc). 2019 Jan;55(1):5-15. doi: 10.1358/dot.2019.55.1.2914339. Review.

PMID:
30740608
7.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R.

Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.

8.

Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas.

Hernandez AL, Wang Y, Somerset HL, Keysar SB, Aisner DL, Marshall C, Bowles DW, Karam SD, Raben D, Jimeno A, Varella-Garcia M, Wang XJ.

Mol Carcinog. 2019 May;58(5):666-673. doi: 10.1002/mc.22958. Epub 2019 Jan 16.

9.

Wnt signaling dynamics in head and neck squamous cell cancer tumor-stroma interactions.

Le PN, Keysar SB, Miller B, Eagles JR, Chimed TS, Reisinger J, Gomez KE, Nieto C, Jackson BC, Somerset HL, Morton JJ, Wang XJ, Jimeno A.

Mol Carcinog. 2019 Mar;58(3):398-410. doi: 10.1002/mc.22937. Epub 2018 Nov 28.

PMID:
30378175
10.

A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors.

Jimeno A, Moore KN, Gordon M, Chugh R, Diamond JR, Aljumaily R, Mendelson D, Kapoun AM, Xu L, Stagg R, Smith DC.

Invest New Drugs. 2019 Jun;37(3):461-472. doi: 10.1007/s10637-018-0665-y. Epub 2018 Sep 19.

PMID:
30229512
11.

Dual use of hematopoietic and mesenchymal stem cells enhances engraftment and immune cell trafficking in an allogeneic humanized mouse model of head and neck cancer.

Morton JJ, Keysar SB, Perrenoud L, Chimed TS, Reisinger J, Jackson B, Le PN, Nieto C, Gomez K, Miller B, Gao D, Somerset H, Wang XJ, Jimeno A.

Mol Carcinog. 2018 Nov;57(11):1651-1663. doi: 10.1002/mc.22887. Epub 2018 Sep 3.

PMID:
30129680
12.

Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer.

Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, Somerset H, Marshall C, Young C, Davies KD, Kane M, Tan AC, Wang XJ, Jimeno A, Aisner DL, Bowles DW, Raben D.

Clin Cancer Res. 2018 Oct 15;24(20):4949-4959. doi: 10.1158/1078-0432.CCR-18-0467. Epub 2018 Jul 3.

13.

Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial.

Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW.

JAMA Oncol. 2018 Nov 1;4(11):1583-1588. doi: 10.1001/jamaoncol.2018.1888.

14.

Inhibition of EphB4-Ephrin-B2 Signaling Enhances Response to Cetuximab-Radiation Therapy in Head and Neck Cancers.

Bhatia S, Sharma J, Bukkapatnam S, Oweida A, Lennon S, Phan A, Milner D, Uyanga N, Jimeno A, Raben D, Somerset H, Heasley L, Karam SD.

Clin Cancer Res. 2018 Sep 15;24(18):4539-4550. doi: 10.1158/1078-0432.CCR-18-0327. Epub 2018 May 30.

15.

Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.

Sharma P, King GT, Shinde SS, Purev E, Jimeno A.

Drugs Today (Barc). 2018 Mar;54(3):187-198. doi: 10.1358/dot.2018.54.3.2776625. Review.

PMID:
29771253
16.

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018.

Colevas AD, Yom SS, Pfister DG, Spencer S, Adelstein D, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Eisele DW, Fenton M, Foote RL, Gilbert J, Gillison ML, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2018 May;16(5):479-490. doi: 10.6004/jnccn.2018.0026.

17.

Immune and autoimmune-related adverse events associated with immune checkpoint inhibitors in cancer therapy.

King GT, Sharma P, Davis SL, Jimeno A.

Drugs Today (Barc). 2018 Feb;54(2):103-122. doi: 10.1358/dot.2018.54.2.2776626. Review.

PMID:
29637937
18.

Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression.

Keysar SB, Eagles JR, Miller B, Jackson BC, Chowdhury FN, Reisinger J, Chimed TS, Le PN, Morton JJ, Somerset HL, Varella-Garcia M, Tan AC, Song JI, Bowles DW, Reyland ME, Jimeno A.

Clin Cancer Res. 2018 Jun 15;24(12):2935-2943. doi: 10.1158/1078-0432.CCR-17-3871. Epub 2018 Mar 19.

19.

Bispecific antibodies for cancer therapy: A review.

Krishnamurthy A, Jimeno A.

Pharmacol Ther. 2018 May;185:122-134. doi: 10.1016/j.pharmthera.2017.12.002. Epub 2017 Dec 18. Review.

PMID:
29269044
20.

FYCO1 regulates accumulation of post-mitotic midbodies by mediating LC3-dependent midbody degradation.

Dionne LK, Peterman E, Schiel J, Gibieža P, Skeberdis VA, Jimeno A, Wang XJ, Prekeris R.

J Cell Sci. 2017 Dec 1;130(23):4051-4062. doi: 10.1242/jcs.208983.

21.

Phase I Study of Enavatuzumab, a First-in-Class Humanized Monoclonal Antibody Targeting the TWEAK Receptor, in Patients with Advanced Solid Tumors.

Lam ET, Eckhardt SG, Messersmith W, Jimeno A, O'Bryant CL, Ramanathan RK, Weiss GJ, Chadha M, Oey A, Ding HT, Culp PA, Keller SF, Zhao VY, Tsao LC, Singhal A, Holen KD, Von Hoff D.

Mol Cancer Ther. 2018 Jan;17(1):215-221. doi: 10.1158/1535-7163.MCT-17-0330. Epub 2017 Oct 20.

22.

A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafricept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors.

Jimeno A, Gordon M, Chugh R, Messersmith W, Mendelson D, Dupont J, Stagg R, Kapoun AM, Xu L, Uttamsingh S, Brachmann RK, Smith DC.

Clin Cancer Res. 2017 Dec 15;23(24):7490-7497. doi: 10.1158/1078-0432.CCR-17-2157. Epub 2017 Sep 27.

23.

Long-Term Follow-Up of Desmoid Fibromatosis Treated with PF-03084014, an Oral Gamma Secretase Inhibitor.

Villalobos VM, Hall F, Jimeno A, Gore L, Kern K, Cesari R, Huang B, Schowinsky JT, Blatchford PJ, Hoffner B, Elias A, Messersmith W.

Ann Surg Oncol. 2018 Mar;25(3):768-775. doi: 10.1245/s10434-017-6082-1. Epub 2017 Sep 8.

PMID:
28887726
24.

NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017.

Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD.

J Natl Compr Canc Netw. 2017 Jun;15(6):761-770. doi: 10.6004/jnccn.2017.0101.

25.

Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers.

Krishnamurthy A, Jimeno A.

Drugs Today (Barc). 2017 Apr;53(4):217-237. doi: 10.1358/dot.2017.53.4.2589163. Review.

PMID:
28492290
26.

Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy.

Rusthoven CG, Lanning RM, Jones BL, Amini A, Koshy M, Sher DJ, Bowles DW, McDermott JD, Jimeno A, Karam SD.

Radiother Oncol. 2017 Jul;124(1):139-146. doi: 10.1016/j.radonc.2017.03.019. Epub 2017 Apr 19.

PMID:
28433411
27.

EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.

Vaishnavi A, Schubert L, Rix U, Marek LA, Le AT, Keysar SB, Glogowska MJ, Smith MA, Kako S, Sumi NJ, Davies KD, Ware KE, Varella-Garcia M, Haura EB, Jimeno A, Heasley LE, Aisner DL, Doebele RC.

Cancer Res. 2017 Jul 1;77(13):3551-3563. doi: 10.1158/0008-5472.CAN-17-0109. Epub 2017 Apr 20.

28.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR.

JCI Insight. 2017 Mar 23;2(6):e90449. doi: 10.1172/jci.insight.90449.

29.

Cobimetinib: inhibiting MEK1/2 in BRAF V600-mutant melanoma.

Eagles JR, Jimeno A.

Drugs Today (Barc). 2016 Nov;52(11):593-605. doi: 10.1358/dot.2016.52.11.2542234. Review.

PMID:
28112278
30.

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.

Jimeno A, Sharma MR, Szyldergemajn S, Gore L, Geary D, Diamond JR, Fernandez Teruel C, Soto Matos-Pita A, Iglesias JL, Cullell-Young M, Ratain MJ.

Invest New Drugs. 2017 Aug;35(4):471-477. doi: 10.1007/s10637-017-0427-2. Epub 2017 Jan 20.

PMID:
28105566
31.

Enhancing radiosensitization in EphB4 receptor-expressing Head and Neck Squamous Cell Carcinomas.

Bhatia S, Hirsch K, Sharma J, Oweida A, Griego A, Keysar S, Jimeno A, Raben D, Krasnoperov V, Gill PS, Pasquale EB, Wang XJ, Karam SD.

Sci Rep. 2016 Dec 12;6:38792. doi: 10.1038/srep38792.

32.
33.

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study).

Fayette J, Wirth L, Oprean C, Udrea A, Jimeno A, Rischin D, Nutting C, Harari PM, Csoszi T, Cernea D, O'Brien P, Hanley WD, Kapp AV, Anderson M, Penuel E, McCall B, Pirzkall A, Vermorken JB.

Front Oncol. 2016 Oct 31;6:232. eCollection 2016.

34.

Humanized Mouse Xenograft Models: Narrowing the Tumor-Microenvironment Gap.

Morton JJ, Bird G, Refaeli Y, Jimeno A.

Cancer Res. 2016 Nov 1;76(21):6153-6158. Epub 2016 Sep 1. Review.

35.

Ephrin-B2 overexpression predicts for poor prognosis and response to therapy in solid tumors.

Oweida A, Bhatia S, Hirsch K, Calame D, Griego A, Keysar S, Pitts T, Sharma J, Eckhardt G, Jimeno A, Wang XJ, Parkash G, Califano J, Karam SD.

Mol Carcinog. 2017 Mar;56(3):1189-1196. doi: 10.1002/mc.22574. Epub 2016 Nov 1.

36.

A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Posner MR, Wirth LJ, Saba NF, Cohen RB, Popa EC, Argiris A, Grossmann KF, Sukari A, Wilson D, Zhang X, Sun J, Glasser C, Attie KM, Sherman ML, Pandya SS, Weiss J.

Cancer. 2016 Dec 1;122(23):3641-3649. doi: 10.1002/cncr.30317. Epub 2016 Sep 20.

37.

Cancer Stem Cells in Squamous Cell Carcinoma.

Jian Z, Strait A, Jimeno A, Wang XJ.

J Invest Dermatol. 2017 Jan;137(1):31-37. doi: 10.1016/j.jid.2016.07.033. Epub 2016 Nov 24. Review.

38.

Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.

Keysar SB, Le PN, Miller B, Jackson BC, Eagles JR, Nieto C, Kim J, Tang B, Glogowska MJ, Morton JJ, Padilla-Just N, Gomez K, Warnock E, Reisinger J, Arcaroli JJ, Messersmith WA, Wakefield LM, Gao D, Tan AC, Serracino H, Vasiliou V, Roop DR, Wang XJ, Jimeno A.

J Natl Cancer Inst. 2016 Sep 15;109(1). doi: 10.1093/jnci/djw189. Print 2017 Jan.

39.

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.

Jimeno A, Machiels JP, Wirth L, Specenier P, Seiwert TY, Mardjuadi F, Wang X, Kapp AV, Royer-Joo S, Penuel E, McCall B, Pirzkall A, Clement PM.

Cancer. 2016 Dec 15;122(24):3803-3811. doi: 10.1002/cncr.30256. Epub 2016 Aug 15.

40.

Emerging from their burrow: Hedgehog pathway inhibitors for cancer.

Gan GN, Jimeno A.

Expert Opin Investig Drugs. 2016 Oct;25(10):1153-66. doi: 10.1080/13543784.2016.1216973. Epub 2016 Aug 5. Review.

PMID:
27459882
41.

A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma.

Bowles DW, Kochenderfer M, Cohn A, Sideris L, Nguyen N, Cline-Burkhardt V, Schnadig I, Choi M, Nabell L, Chaudhry A, Ruxer R, Ucar A, Hausman D, Walker L, Spira A, Jimeno A.

Clin Colorectal Cancer. 2016 Dec;15(4):337-344.e2. doi: 10.1016/j.clcc.2016.03.004. Epub 2016 Mar 31.

PMID:
27118441
42.

Palbociclib:CDK4/6 inhibition in the treatment of ER-positive breast cancer.

Owsley J, Jimeno A, Diamond JR.

Drugs Today (Barc). 2016 Feb;52(2):119-29. doi: 10.1358/dot.2016.52.2.2440528. Review.

PMID:
27092341
43.

Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base.

Amini A, Jasem J, Jones BL, Robin TP, McDermott JD, Bhatia S, Raben D, Jimeno A, Bowles DW, Karam SD.

Oral Oncol. 2016 May;56:1-7. doi: 10.1016/j.oraloncology.2016.02.011. Epub 2016 Mar 12.

PMID:
27086480
44.

Outbreak of urinary tract infections by Salmonella spp. after cystoscopic manipulation.

Jimeno A, Alcalde MM, Ortiz M, Rodríguez A, Alcaraz B, Vera F.

Actas Urol Esp. 2016 Dec;40(10):646-649. doi: 10.1016/j.acuro.2016.02.005. Epub 2016 Apr 6. English, Spanish.

PMID:
27061662
45.

Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.

Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Green JA, Steer C, Berns EM, Casado A, Lambrechts D, Jimeno A.

Target Oncol. 2016 Jun;11(3):429. No abstract available.

PMID:
27056749
46.

Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base.

Amini A, Jones BL, McDermott JD, Serracino HS, Jimeno A, Raben D, Ghosh D, Bowles DW, Karam SD.

Cancer. 2016 May 15;122(10):1533-43. doi: 10.1002/cncr.29956. Epub 2016 Mar 11.

47.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

O'Neil BH, Scott AJ, Ma WW, Cohen SJ, Aisner DL, Menter AR, Tejani MA, Cho JK, Granfortuna J, Coveler AL, Olowokure OO, Baranda JC, Cusnir M, Phillip P, Boles J, Nazemzadeh R, Rarick M, Cohen DJ, Radford J, Fehrenbacher L, Bajaj R, Bathini V, Fanta P, Berlin J, McRee AJ, Maguire R, Wilhelm F, Maniar M, Jimeno A, Gomes CL, Messersmith WA.

Ann Oncol. 2016 Jun;27(6):1180. doi: 10.1093/annonc/mdw095. Epub 2016 Mar 3. No abstract available.

PMID:
26945010
48.

Olaparib for the treatment of ovarian cancer.

Bornstein E, Jimeno A.

Drugs Today (Barc). 2016 Jan;52(1):17-28. doi: 10.1358/dot.2016.52.1.2440714. Review.

PMID:
26937492
49.

A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.

Bowles DW, Keysar SB, Eagles JR, Wang G, Glogowska MJ, McDermott JD, Le PN, Gao D, Ray CE, Rochon PJ, Roop DR, Tan AC, Serracino HS, Jimeno A.

Oral Oncol. 2016 Feb;53:74-9. doi: 10.1016/j.oraloncology.2015.11.014. Epub 2015 Dec 15.

50.

DNA Damage Response Proteins and Oxygen Modulate Prostaglandin E2 Growth Factor Release in Response to Low and High LET Ionizing Radiation.

Allen CP, Tinganelli W, Sharma N, Nie J, Sicard C, Natale F, King M 3rd, Keysar SB, Jimeno A, Furusawa Y, Okayasu R, Fujimori A, Durante M, Nickoloff JA.

Front Oncol. 2015 Dec 7;5:260. doi: 10.3389/fonc.2015.00260. eCollection 2015.

Supplemental Content

Loading ...
Support Center